Profound Properties of Protein-Rich, Platelet-Rich Plasma Matrices as Novel, Multi-Purpose Biological Platforms in Tissue Repair, Regeneration, and Wound Healing.

fibrin(ogen) matrix platelet-rich plasma protein-rich platelet concentrate tissue regeneration tissue repair ultrafiltration

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
19 Jul 2024
Historique:
received: 26 05 2024
revised: 07 07 2024
accepted: 17 07 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 27 7 2024
Statut: epublish

Résumé

Autologous platelet-rich plasma (PRP) preparations are prepared at the point of care. Centrifugation cellular density separation sequesters a fresh unit of blood into three main fractions: a platelet-poor plasma (PPP) fraction, a stratum rich in platelets (platelet concentrate), and variable leukocyte bioformulation and erythrocyte fractions. The employment of autologous platelet concentrates facilitates the biological potential to accelerate and support numerous cellular activities that can lead to tissue repair, tissue regeneration, wound healing, and, ultimately, functional and structural repair. Normally, after PRP preparation, the PPP fraction is discarded. One of the less well-known but equally important features of PPP is that particular growth factors (GFs) are not abundantly present in PRP, as they reside outside of the platelet alpha granules. Precisely, insulin-like growth factor-1 (IGF-1) and hepatocyte growth factor (HGF) are mainly present in the PPP fraction. In addition to their roles as angiogenesis activators, these plasma-based GFs are also known to inhibit inflammation and fibrosis, and they promote keratinocyte migration and support tissue repair and wound healing. Additionally, PPP is known for the presence of exosomes and other macrovesicles, exerting cell-cell communication and cell signaling. Newly developed ultrafiltration technologies incorporate PPP processing methods by eliminating, in a fast and efficient manner, plasma water, cytokines, molecules, and plasma proteins with a molecular mass (weight) less than the pore size of the fibers. Consequently, a viable and viscous protein concentrate of functional total proteins, like fibrinogen, albumin, and alpha-2-macroglobulin is created. Consolidating a small volume of high platelet concentrate with a small volume of highly concentrated protein-rich PPP creates a protein-rich, platelet-rich plasma (PR-PRP) biological preparation. After the activation of proteins, mainly fibrinogen, the PR-PRP matrix retains and facilitates interactions between invading resident cells, like macrophages, fibroblast, and mesenchymal stem cells (MSCs), as well as the embedded concentrated PRP cells and molecules. The administered PR-PRP biologic will ultimately undergo fibrinolysis, leading to a sustained release of concentrated cells and molecules that have been retained in the PR-PRP matrix until the matrix is dissolved. We will discuss the unique biological and tissue reparative and regenerative properties of the PR-PRP matrix.

Identifiants

pubmed: 39063156
pii: ijms25147914
doi: 10.3390/ijms25147914
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Peter A Everts (PA)

Gulf Coast Biologics, A Non-Profit Organization, Fort Myers, FL 33916, USA.
OrthoRegen Group, Max-Planck University, Indaiatuba 13334-170, SP, Brazil.

José Fábio Lana (JF)

OrthoRegen Group, Max-Planck University, Indaiatuba 13334-170, SP, Brazil.

Robert W Alexander (RW)

Regenevita Biocellular Aesthetic & Reconstructive Surgery, Cranio-Maxillofacial Surgery, Regenerative and Wound Healing, Hamilton, MT 59840, USA.
Department of Surgery & Maxillofacial Surgery, School of Medicine & Dentistry, University of Washington, Seattle, WA 98195, USA.

Ignacio Dallo (I)

Unit of Biological Therapies and MSK Interventionism, Department of Orthopaedic Surgery and Sports Medicine, Sport Me Medical Center, 41013 Seville, Spain.

Elizaveta Kon (E)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy.
IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.

Mary A Ambach (MA)

BioEvolve, San Diego Orthobiologics and Sports Center, San Diego, CA 92024, USA.

André van Zundert (A)

Department of Anaesthesia and Perioperative Medicine, Royal Brisbane and Women's Hospital, Brisbane and The University of Queensland, Brisbane 4072, Australia.

Luga Podesta (L)

Bluetail Medical Group & Podesta Orthopedic Sports Medicine, Naples, FL 34109, USA.
Physical Medicine & Rehabilitation Orlando College of Osteopathic Medicine, Orlando, FL 32806, USA.

Classifications MeSH